LENZ Therapeutics, Inc. Common Stock
LENZLENZ Therapeutics, Inc. (LENZ) is a biotechnology company focused on developing innovative treatments for neurological and psychiatric disorders. The company specializes in designing targeted therapies that address unmet medical needs, leveraging cutting-edge research and technology to improve patient outcomes in areas such as neurodegenerative diseases and mental health conditions.
Company News
LENZ Therapeutics announced that Everest Medicines has acquired rights to develop and commercialize VIZZ (LNZ100) in Greater China through an Asset Purchase Agreement with Corxel Pharmaceuticals. The New Drug Application for LNZ100 was submitted to China's NMPA in September 2025 with approval anticipated in Q1 2027. LENZ is eligible to receive up...
The presbyopia market is projected to grow at a CAGR of 4.9% from 2026-2036, driven by an aging global population and expanding treatment options. The market was valued at USD 11 billion in 2025 across seven major markets, with the US accounting for 50% of the market. Multiple emerging therapies and devices are expected to enter the market, inclu...
Lenz Therapeutics stock plummeted 11.2% after missing Q4 earnings and sales expectations. The vision drug company reported a loss of $1.16 per share on $1.6 million in sales, versus analyst forecasts of $0.90 loss on $3.1 million in sales. Despite being on pace for 45,000 VIZZ prescriptions by end of Q1 2026, weak launch quarter uptake and quadru...
Lenz Therapeutics reported $5.0 million in Q2 2025 revenue from licensing deals, exceeding analyst expectations. The company is preparing for FDA review of LNZ100, an eye drop for presbyopia, with a decision expected by August 8, 2025. Despite increased operating expenses leading to a wider net loss, Lenz remains focused on commercial readiness.
Capstone data from Phase 3 CLARITY study to be presented
